Observes upadacitinib use in adults with ulcerative colitis in China
Checks how well upadacitinib works and its safety in Chinese adults with ulcerative colitis.
Plain-language title generated from the registry record
Registry title: An Observational Study to Evaluate Effectiveness and Safety of Upadacitinib in Chinese Adult Participants With Moderate to Severely Active Ulcerative Colitis (UC)
Key facts
- Where
- Guangzhou and Zhengzhou, ChinaSee the 3 sites
Where in China
- The First Affiliated Hospital, Sun-Yat Sen University /ID# 272997Guangzhou, ChinaTaking people
- The Sixth Affiliated Hospital of Sun Yat-sen University /ID# 274753Guangzhou, ChinaTaking people
- The Second Affiliated Hospital Of Zhengzhou University /ID# 274754Zhengzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AbbVie
- Trial code
- NCT06838845
- Record updated
- 26 November 2025
- Original description
Ulcerative colitis (UC) is a chronic, relapsing, and incurable inflammatory disease of the large intestine. The hallmark clinical symptoms include bloody diarrhea associated with rectal urgency and tenesmus.. This study will assess how effective upadacitinib is in treating UC within a Chinese population.Read full original descriptionShow less
Prospective Observational Study Of Upadacitinib in Ulcerative Colitis in China
Ulcerative colitis (UC) is a chronic, relapsing, and incurable inflammatory disease of the large intestine. The hallmark clinical symptoms include bloody diarrhea associated with rectal urgency and tenesmus.. This study will assess how effective upadacitinib is in treating UC within a Chinese population.
Upadacitinib is an approved drug for treating UC. Approximately 80 adult participants, who have been prescribed upadacitinib for UC by their physician in accordance with local label, will be enrolled in China.
Upadacitinib will be administered in accordance with the terms of the local marketing authorization, and treatment of participants will be determined solely by the investigator. Participants in the study will be followed for up to 1 year.
There will be no additional burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and only data which are routinely collected during a regular visit will be utilized for this study.
Inclusion: Chinese participants meet the diagnosis of moderately to severely active Ulcerative colitis (UC); Participants prescribed upadacitinib at discretion of their treating physicians based on sufficient consideration of benefits/risks for patients per local label; Participant must be an adult (≥ 18 years); Participant must provide written authorization to use personal and/or health data prior to the entry into the study.
Exclusion: Participant participating in any interventional trials; Participant with any contraindication to upadacitinib as listed on the local China label; Participant unwilling or unable to comply with the study requirements, including completion of patient reported outcome questionnaires.